Exact Sciences Co. (NASDAQ: EXAS) Expected to Post Fiscal 2023 Earnings of ($ 1.23) Per Share
Exact Sciences Co. (NASDAQ: EXAS) – Research analysts at SVB Leerink released their earnings per share (EPS) estimates for fiscal 2023 for Exact Sciences in a research report released on Wednesday, November 3. SVB Leerink analyst P. Souda predicts the medical research company will earn ($ 1.23) per share for the year. SVB Leerink currently has an âOutperformanceâ rating and a target share price of $ 140.00.
A number of other research companies have also recently commented on EXAS. Wells Fargo & Company reduced its price target on Exact Sciences from $ 120.00 to $ 95.00 and set an “equal weight” rating for the company in a research report released Wednesday. Cowen reduced his price target on Exact Sciences from $ 160.00 to $ 135 and established an “outperformance” rating for the company in a research report released Thursday, October 14. Canaccord Genuity reduced its price target on Exact Sciences from $ 185.00 to $ 160.00 and established a âbuyâ rating for the company in a research report on Thursday, July 29. BTIG Research reduced its price target on Exact Sciences from $ 145.00 to $ 120.00 and set a “buy” rating for the company in a research report released Wednesday. Finally, Raymond James reduced Exact Sciences from a “strong buy” rating to an “outperform” rating and lowered its price target for the company from $ 160.00 to $ 130.00 in a research report published Wednesday. One investment analyst rated the stock with a sell rating, another issued a custody rating, and twelve issued a buy rating for the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $ 136.64.
Exact science actions open for $ 94.32 Thursday. The stock has a market cap of $ 16.22 billion, a PE ratio of -18.98 and a beta of 1.21. Exact Sciences has a 12-month low of $ 85.82 and a 12-month high of $ 159.54. The company has a 50-day simple moving average of $ 98.87 and a 200-day simple moving average of $ 108.24. The company has a debt ratio of 0.53, a current ratio of 2.47, and a quick ratio of 2.34. Exact Sciences (NASDAQ: EXAS) last reported its quarterly results on Monday, November 1. The medical research firm reported ($ 0.97) earnings per share (EPS) for the quarter, missing ($ 0.08) Zacks’ consensus estimate of ($ 0.89). Exact Sciences posted a negative net margin of 46.14% and a negative return on equity of 11.63%. During the same period last year, the company made earnings per share ($ 0.36).
Energy needs are increasing and natural gas is a much better alternative to coal.
Separately, CEO Kevin T. Conroy sold 17,078 shares of the company in a trade on Friday, October 1. The stock was sold for an average price of $ 93.64, for a total value of $ 1,599,183.92. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Additionally, CEO Kevin T. Conroy sold 16,922 shares of the company in a trade on Monday, November 1. The shares were sold for an average price of $ 93.88, for a total value of $ 1,588,637.36. Disclosure of this sale can be found here. 1.40% of the shares are currently owned by insiders.
Several institutional investors have recently changed their positions in the company. Price T Rowe Associates Inc. MD increased its stake in Exact Sciences shares by 8.2% in the second quarter. Price T Rowe Associates Inc. MD now owns 19,789,343 shares of the medical research company valued at $ 2,460,013,000 after purchasing an additional 1,495,404 shares in the last quarter. Vanguard Group Inc. increased its stake in Exact Sciences shares by 2.0% in the 2nd quarter. Vanguard Group Inc. now owns 15,410,555 shares of the medical research company valued at $ 1,915,686,000 after purchasing an additional 307,132 shares in the last quarter. ARK Investment Management LLC increased its stake in Exact Sciences shares by 17.3% in the 2nd quarter. ARK Investment Management LLC now owns 10,726,790 shares of the medical research company valued at $ 1,333,447,000 after purchasing an additional 1,578,155 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its stake in Exact Sciences by 25.0% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,679,730 shares of the medical research company valued at $ 446,680,000 after acquiring an additional 936,245 shares in the last quarter. Finally, Baillie Gifford & Co. increased its stake in Exact Sciences by 2.7% during the second quarter. Baillie Gifford & Co. now owns 4,466,127 shares of the medical research company valued at $ 555,184,000 after acquiring 119,101 additional shares in the last quarter. 88.78% of the shares are currently held by institutional investors and hedge funds.
Company Profile Exact Sciences
EXACT Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. She developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.
Read more: What does a neutral equity rating mean?
This instant news alert was powered by storytelling technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [emailÂ protected]
Should you invest $ 1,000 in the exact sciences now?
Before you consider the exact sciences, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold … and Exact Sciences was not on the list.
While Exact Sciences currently has a âBuyâ rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here